^
Association details:
| Biomarker: | NRG1 overexpression |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
Published date:
04/23/2022
Excerpt:
Immunoblot analysis revealed that NRG1 expression was relatively high in cetuximab-resistant HNC PDXs compared to cetuximab-sensitive HNC PDXs.
DOI:
10.1186/s12885-022-09511-6
